John Wayne Cancer Institute

Santa Monica, CA, United States

John Wayne Cancer Institute

Santa Monica, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
John Wayne Cancer Institute | Date: 2016-10-13

In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.


Morton D.L.,John Wayne Cancer Institute
Clinical and Experimental Metastasis | Year: 2012

This short review offers an update on the first and second Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) for patients with melanoma, and briefly traces the development of intraoperative lymphatic mapping and sentinel node biopsy. © Springer Science+Business Media B.V. 2012.


Morad S.A.F.,John Wayne Cancer Institute | Cabot M.C.,John Wayne Cancer Institute
Nature Reviews Cancer | Year: 2013

One crucial barrier to progress in the treatment of cancer has been the inability to control the balance between cell proliferation and apoptosis: enter ceramide. Discoveries over the past 15 years have elevated this sphingolipid to the lofty position of a regulator of cell fate. Ceramide, it turns out, is a powerful tumour suppressor, potentiating signalling events that drive apoptosis, autophagic responses and cell cycle arrest. However, defects in ceramide generation and metabolism in cancer cells contribute to tumour cell survival and resistance to chemotherapy. This Review focuses on ceramide signalling and the targeting of specific metabolic junctures to amplify the tumour suppressive activities of ceramide. The potential of ceramide-based therapeutics in the treatment of cancer is also discussed. © 2013 Macmillan Publishers Limited. All rights reserved.


Singer F.R.,John Wayne Cancer Institute
Cell Metabolism | Year: 2011

Studies of the etiology of Paget's disease have focused separately on the viral and genetic components of the disease. In this issue of Cell Metabolism, Kurihara et al. (2011) join these components, reporting that sequestosome 1 mutation in patients and mice activates osteoclasts, while measles virus induces the phenotype of Paget's disease. © 2011 Elsevier Inc.


Patent
John Wayne Cancer Institute | Date: 2016-03-14

Disclosed are methods of predicting whether a subjects metastatic breast cancer is stable or progressive are provided. Such methods may include measuring T cell subsets in a fluid sample of the subject; and predicting whether the subjects metastatic breast cancer is likely to be stable or progressive when there is an elevated ratio of the T cell subsets. Also disclosed are methods of treating metastatic breast cancer by a conservative therapy or an aggressive therapy based on the determination of a stable or progressive cancer.


In one embodiment, a method of theranostic classification of a breast cancer tumor is provided, comprising obtaining a breast cancer tumor sample from a subject, detecting an expression level of FOXC1, comparing the expression level of FOXC1 to a predetermined cutoff level, and classifying the breast cancer tumor sample as belonging to a theranostic basal-like breast cancer tumor subtype or a theranostic hybrid basal-like breast cancer tumor subtype when the expression level of FOXC1 is higher than the predetermined cutoff level. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided,


In some embodiments, methods of determining that a subject is likely to have cancer are provided. Such methods may include amplifying a microbial DNA sample in a test sample obtained from the subject to determine an amount of microbial DNA in the test sample, wherein the amount of microbial DNA is determined by an amplification or sequencing technique; and determining that the subject is likely to have breast cancer when there is a significantly decreased level of microbial DNA in the test sample when compared to a level of microbial DNA in a control sample. In other embodiments, methods of treating cancer (e.g., breast cancer) are provided. In one aspect, such methods include administering a therapeutically effective dose of a probiotic organism via ductal lavage to a subject suffering from the breast cancer.


Patent
John Wayne Cancer Institute | Date: 2015-09-23

The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis.


Patent
John Wayne Cancer Institute | Date: 2015-05-04

Methods for diagnosis and treatment of cancer using ID4 are disclosed. Specifically, epigenetic inactivation of ID4 in colorectal carcinomas and breast correlates with poor differentiation and unfavorable prognosis. Further, aberrant hypermethylation of ID4 gene promoter region increases risk of metastasis in colorectal and breast cancer.


Patent
John Wayne Cancer Institute | Date: 2015-06-26

A method of detecting circulating DNA in a body fluid. The method comprises identifying a subject suffering from or at risk for developing cancer, obtaining a body fluid sample from the subject, and determining the sequence integrity of circulating DNA in the sample, wherein the circulating DNA is not purified from the sample.

Loading John Wayne Cancer Institute collaborators
Loading John Wayne Cancer Institute collaborators